Biopharma Group to launch new GMP freeze drying production facility
Opening soon, Biopharma Group’s new GMP freeze drying production facility is set to provide a much needed resource to pharmaceutical companies needing small batch production facilities for first-in-human clinical trials. With construction having started in 2023, the new GMP facility in Winchester, UK, will provide freeze drying for up to 3,200 2R vials in their state-of-the-art ATS Hull S10 freeze dryer, along with full isolation facilities in a grade A cleanroom environment for sterile production of both liquid and lyophilised products.
Global Commercial Manager for Biopharma Group, Tim Lewis, said:
“There is a dearth of small scale lyophilised GMP facilities in the UK and Europe and the opening of the new GMP production facility will help provide a service that is currently in short supply to our customers. The additional ability to work with cytotoxic compounds allows us to tailor our service to customers’ GMP needs. Our ability to work on products from first principles, through research and development and finally to GMP production, gives us a unique and unmatched understanding of customers products and the processes that we apply to them”.
Biopharma Group is a leading CDMO in the freeze-drying industry, working with leading pharma and diagnostics companies to turn liquid products into freeze dried versions, giving huge benefits in stability, shelf-life and removal of cold-chain logistics.
The new GMP production facility is based at Biopharma Group’s UK headquarters in Winchester and will be available for customer use from Q1, 2024. To discuss your GMP requirements contact us today.